R2 Unveils First System to Optimize CAD Display for Digital Mammography
Share:
New Citra(TM) Mammography Applications Suite Available with Sectra Breast Imaging Workstation
CHICAGO, Nov. 28 / -- R2 Technology, Inc., the leader in computer aided detection (CAD) technology for the earlier detection of breast cancer and other medical conditions, today unveiled its new Citra(TM) Mammography Applications Suite, for use with Sectra's multi-modality, vendor- neutral, universal breast imaging workstation. Citra is the first system to "CAD-enable" digital mammography reading workflow, offering the radiologist unique decision support tools and superior productivity during review of mammography cases. Citra will make its worldwide debut here at the 91st Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Booth #8532 (North Hall).
"R2's CAD systems already offer physicians a 'second set of eyes' to help improve the earlier detection of cancer," said John Pavlidis, R2's president and chief executive officer. "With Citra, we now also offer physicians a universal and 'CAD-intelligent' system for reviewing digital mammography images and comparing them with digitized prior film images. Citra optimizes R2 CAD information presentation to assist the radiologist in review and decision- making, while streamlining workflow. This major advance for CAD opens the door to a new world of enhancements powered by CAD-enabled intelligence, especially as many centers migrate to digital mammography."
R2's Citra Mammography Applications Suite works in conjunction with the Sectra IDS5(TM)/mx.net Breast Imaging Workstation and R2 ImageChecker(R) D Mammography CAD System, and is compatible with all FDA-approved full-field digital mammography (FFDM) systems, including those from GE Healthcare, Hologic, Siemens Medical Solutions and Fischer Imaging. Key features of Citra include:
o RightSize(TM) Optimized Temporal Comparison -- An exclusive R2 package that equalizes the size of all displayed images to facilitate the efficient comparison of prior and current images;
o EmphaSize(TM) Variable Size CAD Marks -- R2's exclusive new marker technology provides variable size CAD marks that correlate to lesion significance;
o PeerView(TM) Digital CAD Display -- Enhances the suspicious region in order to help the radiologist understand the specific features detected by R2's algorithm; and
o LesionMetrics(TM) CAD-Enabled Decision Support -- Provides additional information, including lesion size, distance to chest wall and nipple; "R2 CAD Score;" and other characteristics of detected masses and calcifications.
"With CAD increasingly becoming a standard of care in mammography and with many centers' growing transition to digital mammography, it will be important for CAD to have maximum digital functionality," said Dr. Margarita Zuley of Elizabeth Wende Breast Clinic in Rochester, New York. "A universal digital mammography workstation that can help address the current lack of standardization among different vendors' images and the awkwardness of reading and managing both film and digital images will be warmly welcomed by radiologists."
According to the FDA, approximately 9 percent of all mammography systems in the U.S. are digital. This number is expected to grow, following the recent announcement of a major government study showing that digital mammography significantly improves breast cancer detection in certain women.
Five independent prospective clinical studies* from academic and community practices showed that the use of R2's mammography CAD resulted in 6.6 percent to 19.5 percent more cancers detected. Independent studies* comparing CAD performance on architectural distortions, cases graded by difficulty, and small invasive breast cancers all demonstrate the advantage of R2's market- leading CAD algorithm.
R2's ImageChecker system was the first CAD system approved by the U.S. Food and Drug Administration (FDA) for use with film-based mammography in 1998 and for digital mammography in 2001. Since 1998, the company has received multiple supplemental approvals for technological and clinical advances and owns or has exclusive worldwide rights in more than 120 issued and pending patents. To date, more than 2000 ImageChecker CAD systems have been sold worldwide and this year approximately nine million women will have their mammograms interpreted with the aid of R2's leading technology.
About R2 Technology, Inc.
R2 Technology, Inc., headquartered in Sunnyvale, CA, is the recognized leader in the development and commercialization of computer aided detection (CAD), an innovative technology that assists physicians in the earlier detection of breast cancer, actionable lung nodules and other lung abnormalities. As a medical imaging company dedicated to diagnostic decision support, increasing physician productivity and preventing medical errors, R2 Technology is developing CAD systems for a variety of imaging modalities and disease states. For more information, visit www.r2tech.com or call 866-243- 2533.
NOTE: ImageChecker is a registered trademark of R2 Technology, Inc.
* Studies available upon request.
CONTACT: Tracy Morris of R2 Technology, Inc., +1-650-473-1272, or tracy@morrismarcom.com
